SIRT1 Is a Potential Drug Target for Treatment of Diabetic Kidney Disease

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• Sirtuin-1 (SIRT1) deacetylase is crucial for protecting kidney cells against cellular stress.
• SIRT1 demonstrates protective effects in podocytes and renal tubular cells across various kidney diseases, including diabetic kidney disease (DKD).
• SIRT1's renoprotective mechanisms in DKD involve deacetylating key transcription factors like p53, FOXO, RelA/p65NF-κB, STAT3, and PGC1α/PPARγ.

Purpose of the Study:

• To investigate the therapeutic potential of SIRT1 modulation for diabetic kidney disease (DKD).
• To evaluate the efficacy of specific SIRT1 agonists and bromodomain inhibitors in preclinical DKD models.

Main Methods:

• Overexpression of SIRT1 in podocytes to assess its effect on proteinuria and kidney injury in a DKD model.
• Administration of known SIRT1 agonists (resveratrol, puerarin) and a novel specific agonist (BF175) in mouse models of DKD.
• Utilizing a bromodomain inhibitor (MS417) that disrupts the NF-κB/BRD4 interaction to evaluate its impact on DKD.

Main Results:

• Podocyte-specific SIRT1 overexpression attenuated proteinuria and kidney injury in experimental DKD.
• Resveratrol and puerarin diminished diabetic kidney injury in animal models.
• A specific SIRT1 agonist (BF175) significantly reduced kidney injury in type 1 diabetic mice.
• MS417, a bromodomain inhibitor, also attenuated DKD progression.

Conclusions:

• SIRT1 plays a critical renoprotective role in diabetic kidney disease (DKD).
• Specific SIRT1 agonists and bromodomain inhibitors represent promising therapeutic strategies for managing DKD progression.